AGEN - アジェナス (Agenus Inc.) アジェナス

 AGENのチャート


 AGENの企業情報

symbol AGEN
会社名 Agenus Inc (アジェナス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アジェナス(Agenus Inc.)は免疫腫瘍学(I-O)会社である。同社は癌と戦うために身体の免疫システムに関わる治療法の発見と開発に従事する。同社は、ヒト抗体を産生するように設計されたレトロサイトディスプレイ、SECANT酵母ディスプレイおよびファージディスプレイ技術を含む抗体発見プラットフォーム、チェックポイントモジュレーター(CPM)プログラムを含む抗体候補プログラム、並びにProphage、AutoSynVax、PhosPhoSynVax及びQS-21スチムロンアジュバント(QS-21スチムロン)を主とするサポニンベースのワクチンアジュバントを含むワクチンプログラムなどのプラットフォームとプログラムによって駆動されるI-Oポートフォリオを開発している。同社の発見パイプラインには、一連のチェックポイント変調(CPM)抗体が含まれる。ワクチンプラットフォームには、その熱ショックタンパク質(HSP)ベースのプロファージワクチン候補、およびその合成ワクチン候補のASVとPSVが含まれる。   アジェナスは米国のバイオ医薬品メ―カ―。主に、がん治療を目的に、免疫システム機能を調節するチェックポイント調節因子を標的とした抗体医薬品の発見、開発、商用化に従事。脳腫瘍、腎臓がん、肺がん、アルツハイマ―などの免疫治療用ワクチンの研究を行う。本社はマサチュ―セッツ州。   Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA.
本社所在地 3 Forbes Road Lexington MA 02421 USA
代表者氏名 Garo H. Armen ガロ・アーメン
代表者役職名 Chairman of the Board Chief Executive Officer Founder
電話番号 +1 781-674-4410
設立年月日 1994年
市場名 NASDAQ Small Cap
ipoyear 2000年
従業員数 255人
url www.agenusbio.com
nasdaq_url https://www.nasdaq.com/symbol/agen
adr_tso
EBITDA EBITDA(百万ドル) -113.91800
終値(lastsale) 2.07
時価総額(marketcap) 234493980.12
時価総額 時価総額(百万ドル) 223.16580
売上高 売上高(百万ドル) 29.24434
企業価値(EV) 企業価値(EV)(百万ドル) 193.05562
当期純利益 当期純利益(百万ドル) -150.89400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Agenus Inc revenues decreased 44% to $17.5M. Net loss applicable to common stockholders increased 61% to $78.9M. Revenues reflect Revenue (research and development) decrease of 61% to $12.1M. Higher net loss reflects Non-operating income (expense) decrease from $2.4M (income) to $1.4M (expense) GENERAL AND ADMINISTRATIVE increase of 23% to $16.3M (expense).

 AGENのテクニカル分析


 AGENのニュース

   Agenus to Participate in the Raymond James 2021 Human Health Innovation Conference  2021/06/21 13:00:00 Intrado Digital Media
LEXINGTON, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will present at the Raymond James 2021 Human Health Innovation Conference on Tuesday, June 22, 2021 from 8:40 a.m. to 9:10 a.m. ET.
   Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer  2021/06/17 14:23:02 Business Insider Markets
The FDA has accepted for review Agenus Inc''s (NASDAQ: AGEN ) marketing application seeking approval for
   FDA accepts Agenus'' balstilimab BLA under "priority review" status  2021/06/17 12:45:02 Seeking Alpha
   Market Mover: Agenus Inc. (NASDAQ:AGEN), Devon Energy Corporation (NYSE:DVN)  2021/06/13 21:10:49 Stock Equity
Agenus Inc. (NASDAQ:AGEN) with the stream of 0.97% also noticed, India Devon Energy Corporation (NYSE:DVN) encountered a rapid change of 0.45% in the last hour of Fridays trading session. Agenus The post Market Mover: Agenus Inc. (NASDAQ:AGEN), Devon Energy Corporation (NYSE:DVN) appeared first on Stocks Equity .
   Analysts Top Healthcare Picks: Springworks Therapeutics (SWTX), Agenus (AGEN)  2021/06/07 13:15:17 Smarter Analyst
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Springworks Therapeutics (SWTX) and Agenus The post Analysts Top Healthcare Picks: Springworks Therapeutics (SWTX), Agenus (AGEN) appeared first on Smarter Analyst .
   Market Mover: Agenus Inc. (NASDAQ:AGEN), Devon Energy Corporation (NYSE:DVN)  2021/06/13 21:10:49 Stock Equity
Agenus Inc. (NASDAQ:AGEN) with the stream of 0.97% also noticed, India Devon Energy Corporation (NYSE:DVN) encountered a rapid change of 0.45% in the last hour of Fridays trading session. Agenus The post Market Mover: Agenus Inc. (NASDAQ:AGEN), Devon Energy Corporation (NYSE:DVN) appeared first on Stocks Equity .
   Analysts Top Healthcare Picks: Springworks Therapeutics (SWTX), Agenus (AGEN)  2021/06/07 13:15:17 Smarter Analyst
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Springworks Therapeutics (SWTX) and Agenus The post Analysts Top Healthcare Picks: Springworks Therapeutics (SWTX), Agenus (AGEN) appeared first on Smarter Analyst .
   Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy  2021/05/26 07:42:47 Seeking Alpha
   Agenus (AGEN) Soars on Global License Deal With Bristol-Myers  2021/05/22 21:20:55 Yahoo Finance
Agenus (AGEN) Soars on Global License Deal With Bristol-Myers Yahoo Finance
   Agenus Inc Shares Close the Week 29.7% Higher - Weekly Wrap  2021/05/21 22:30:00 Kwhen Finance
Agenus Inc (AGEN) shares closed this week 29.7% higher than it did at the end of last week. The stock is currently up 31.8% year-to-date, up 67.6% over the past 12 months, and up 12.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $4.50 and as low as $3.22 this week.Trading volume this week was 78.4% lower than the 10-day average and 31.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 2063.2% The company's stock price performance over the past 12 months lags the peer average by -34.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Agenus Inc Shares Close the Week 29.7% Higher - Weekly Wrap  2021/05/21 22:30:00 Kwhen Finance
Agenus Inc (AGEN) shares closed this week 29.7% higher than it did at the end of last week. The stock is currently up 31.8% year-to-date, up 67.6% over the past 12 months, and up 12.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $4.50 and as low as $3.22 this week.Trading volume this week was 78.4% lower than the 10-day average and 31.4% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 2063.2% The company's stock price performance over the past 12 months lags the peer average by -34.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アジェナス AGEN Agenus Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)